Halozyme Therapeutics, Inc. Common Stock Earnings Dividend

Halozyme Therapeutics, Inc. Common Stock’s revenue jumped 47.67% since last year same period to $481Mn in the Q2 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated 27.68% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s net profit jumped 39.21% since last year same period to $229.91Mn in the Q2 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated 53.23% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s net profit margin fell -5.73% since last year same period to 47.8% in the Q2 2026. On a quarterly growth basis, Halozyme Therapeutics, Inc. Common Stock has generated 20% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 2.04 - a 17.92% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 2.04.

Halozyme Therapeutics, Inc. Common Stock’s earning per share (EPS) jumped 40.91% since last year same period to 2.17 in the Q2 2026. This indicates that the Halozyme Therapeutics, Inc. Common Stock has generated 40.91% annual rate of jump in its earning per share (EPS) in the last 4 quarters.